$TEM

LEFKOFSKY ERIC P sold $4.6M of TEM (indirect holdings)

LEFKOFSKY ERIC P (CEO and Chairman) sold 97,279 indirectly-held shares of Tempus AI, Inc. (TEM) at $46.89 ($4.56M total) on 2026-05-27 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · LEFKOFSKY ERIC P
Published May 29, 2026, 8:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 29, 2026, 8:20 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$TEM
Neutral
medium confidence
Mentioned
$TEM
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TEMNeutralLow
01

Why it matters

The disclosure may influence short-term sentiment and technical positioning, but the presence of a 10b5-1 plan generally lowers the probability that the sale reflects new negative information.

02

Market read

A $4.56M insider sale is disclosed; traders may watch for any follow-through in sentiment/volume, but the 10b5-1 plan reduces fundamental read-through.

03

What to watch

Consider whether the insider’s remaining stake size or prior sale cadence indicates a pattern; this brief only provides one transaction datapoint.

Relevance 6/10Novelty 6/10Timing: Filed after-hours on 2026-05-29; reflects sale executed 2026-05-27.

Background

This is an SEC Form 4 insider transaction disclosure for Tempus AI, Inc. (TEM).

Company-level read

Ticker impact

$TEMNeutralMedium confidence
Context

Tempus AI CEO/Chairman and 10% owner LEFKOFSKY sold $4.56M of TEM shares in an open-market transaction under a 10b5-1 plan.

Expected impact

Low-to-moderate near-term downside pressure possible, but not a strong directional catalyst.

Evidence & confidence

The filing is a disclosed insider sale (not a buy) with a stated 10b5-1 pre-arranged plan, which typically reduces interpretive weight versus discretionary selling.

Market effects

Minimal; single-company insider transaction without sector-wide catalyst.

Minimal; US-listed micro/SMID cap flow only.

Minimal; no cross-border deal/regulatory element.

Counterpoint

Because the sale was executed under a pre-arranged 10b5-1 plan, it may be routine liquidity rather than a bearish signal.

Key entities

  • Tempus AI, Inc.

    Subject of the insider sale disclosure; CEO/Chairman/10% owner sold shares under a 10b5-1 plan.

  • LEFKOFSKY ERIC P

    CEO and Chairman; executed an open-market sale of 97,279 TEM shares at $46.8900.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$TEMMedAI 8/10

TEM Stock Jumps As Tempus AI Joins Profitable AI Health Elite

Tempus AI Inc. (NASDAQ: TEM) shares rose 14.38% on September 17, 2026, driven by strong Q2 2026 results. Revenue grew 22% YoY to $382.5M, with net income and EBITDA turning positive at $5.6M and $45M, respectively. Gross margin is 73.5%. The company plans to acquire Personalis, funded by $816M in cash and investments, despite $1.36B in long-term debt. TEM's stock has surged from $62 to $80, attracting momentum traders.

$TEMMed

Tempus AI Is Ripping 30% Higher This Week After Morgan Stanley Boosts Revenue Outlook

Tempus AI (TEM) shares surged 29.98% this week after Morgan Stanley highlighted new reimbursement-driven revenue growth. CEO Eric Lefkofsky estimated xT pricing could add $80M-$100M in 2025, and xF approval $250M-$300M annually. Q2 revenue was $382.49M, up 21.6% YoY, with full-year guidance raised to $1.595B-$1.605B. Analysts revised FY2027 EPS estimates positively, with a consensus revenue estimate of $1.97B.

$TEMHighAI 8/10

Tempus AI (TEM) Jumps As Upgrade, Acquisition Fuel Bullish Momentum

Tempus AI Inc. (TEM) shares rose 6.62% after Piper Sandler upgraded it to Overweight with a $76 price target. The company reported Q2 2026 revenue of $382.5M, up 22% YoY, and turned profitable. TEM is acquiring Personalis for $1.5B to expand its tumor-sequencing platform. The stock trades near $66.33, with strong cash position and improving margins.

$MRNAHighAI 9/10

Personalized Cancer Vaccine Breakthrough Ignites Sequencing Sector, Tempus AI's Personalis Bid Faces Rivalry Speculation — BigGo Finance

Moderna and Merck's personalized mRNA cancer vaccine (mRNA-4157) met its primary endpoint in Phase 3 trials, boosting their market value by over $50 billion. The success highlights the role of sequencing companies like Tempus AI and Personalis, which provide genetic profiling for personalized vaccines. Tempus AI's planned acquisition of Personalis faces competition as Personalis' stock surpasses the offer price, sparking speculation of a bidding war. The deal's strategic value lies in Personalis

$TEMHighAI 9/10

Tempus AI gets FDA clearance for pulmonary hypertension AI tool

Tempus AI (NASDAQ: TEM) received FDA clearance for its AI tool, Tempus ECG-PH, which analyzes ECGs for pulmonary hypertension. This is the third FDA-cleared device in its cardiovascular portfolio. Tempus shares rose 5.09% to $70.04, driven by positive Phase 3 trial results from Moderna and Merck, which validate the $1.5 billion acquisition of Personalis.